AACR 2018 Poster Report of Preclinical Rivoceranib (Apatinib) Combination with Immunotherapy
This poster highlights the observed synergistic combination of rivoceranib with anti-PD-1 therapy. The combination significantly improved tumor growth suppression over each agent in monotherapy in a lung cancer mouse model study, which is encouraging for ongoing and upcoming clinical trials of rivoceranib in combination with anti-PD-1 therapies (NCT03396211, NCT03407976). This poster was presented at the 2018 American Association for Cancer Research (AACR) Annual Meeting in Chicago on April 16.
To read the full study report download the poster.